by subject – Page 8 – Retraction Watch

Undisclosed conflicts, lightning-fast peer review: One Alzheimer’s journal’s role in a failed drug

Retraction Watch readers are likely familiar with the work of Charles Piller, an award-winning investigative reporter who has been covering problematic research in neuroscience and other fields for Science. We’re pleased to offer an excerpt of his new book, Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s, which publishes today.

The Journal of Prevention of Alzheimer’s Disease (JPAD) seems authoritative and looks prestigious. Its sponsors are Springer, a division of Springer Nature, one of the largest scientific publishers, and the annual Clinical Trials on Alzheimer’s Disease Congress—a major, global scientific meeting. Many doctors rely on JPAD when deciding whether to prescribe amyloid-reducing drugs such as Leqembi, or others to fight agitation or anxiety that can accompany Alzheimer’s dementia.

Matthew Schrag first raised an eyebrow about the journal in August 2021 while examining possible misconduct in studies behind Cassava Sciences’ simufilam for the citizen petition to the US Food and Drug Administration (FDA). The prior year, JPAD had published a paper by Cassava’s Lindsay Burns and Hoau-Yan Wang that suggested strong potential for the drug. It said simufilam lowered key biomarkers associated with Alzheimer’s—particularly tau proteins—in the spinal fluid of patients who were volunteers for the company’s clinical trial. That paper helped boost confidence in Cassava and simufilam.

More than three decades after misconduct ruling, researcher’s IQ test paper is retracted

A psychology journal has retracted an article on IQ tests nearly 50 years after publication — and more than 35 years after an investigation found the lead author had fabricated data in several other studies.

Stephen Breuning, a former assistant professor of child psychiatry at the University of Pittsburgh, gained notoriety after a 1987 National Institute of Mental Health report found that he “knowingly, willfully, and repeatedly engaged in misleading and deceptive practices in reporting results of research.” The report concluded Breuning had “engaged in serious scientific misconduct” by fabricating results in 10 articles funded by NIMH grants.

Five of Breuning’s articles published in the 1980s have been retracted; three in the 1980s, one in 2022, and another in 2023. Retraction Watch reported on one of them, “Effects of methylphenidate on the fixed-ratio performance of mentally retarded children,” published in 1983 in Pharmacology Biochemistry and Behavior (now published by Elsevier) and retracted in 2022.

The newly retracted article predates those papers. Published in 1978 in the Journal of School Psychology, “Effects of individualized incentives on norm-referenced IQ test performance of high school students in special education classes,” found record albums, sporting event tickets, portable radios, and other incentives boosted scores on IQ tests.

EcoHealth Alliance retracts and replaces paper on potential origin of COVID-19 in bats

The authors of an influential but controversial 2020 paper on the activity of bat coronaviruses in China which proposed the animals as a “likely origin” for the virus that causes COVID-19 have retracted their work and republished a revised version of the analysis. They say their results and conclusions did not change.

The paper, “Origin and cross-species transmission of bat coronaviruses in China,” appeared Aug. 25, 2020, in Nature Communications. It has been cited 154 times, according to Clarivate’s Web of Science, and by at least two international policy documents.

The authors are affiliated with the Wuhan Institute of Virology and the New York City-based nonprofit organization EcoHealth Alliance, which has come under intense scrutiny by members of the U.S. Congress and others. The U.S. government in May suspended funding for EcoHealth amid concerns the COVID-19 pandemic virus may have developed from research on which the nonprofit and Wuhan lab collaborated – a so-called “lab leak.” EcoHealth has denied the pandemic virus could have emerged from its work.

Cancer researcher admitted faking data

A former researcher at Nemours Children’s Health in Wilmington, Del., admitted to falsifying and incorrectly reporting data in at least two published studies, both of which were supported by grants from the National Institutes of Health. The studies have been retracted.

The researcher, Valerie Sampson, reported herself to Nemours, which launched an inquiry into all of her publications, according to a hospital spokesperson. The institution’s findings are under review at the U.S. Office of Research Integrity.

Sampson left Nemours in January 2022 after 16 years with the hospital, according to her LinkedIn profile. She also held a position as an affiliated scientist at the University of Delaware, a role that ended in the same month, per the profile. Six months following her departure from Nemours, Sampson took a position as a scientist at WuXi Advanced Therapies in Philadelphia, a company specializing in cell and gene therapies, for a little over a year. She is currently unemployed, according to the profile.

How an article estimating deaths from hydroxychloroquine use came to be retracted

An article estimating how many people might have died during the first wave of the COVID-19 pandemic due to the off-label use of hydroxychloroquine in hospitals was retracted in August after advocates for the drug launched a campaign criticizing the study.

French media have reported criticism of the retraction as inappropriate, and speculation the journal caved to pressure from hydroxychloroquine advocates.

In a statement to Retraction Watch, the journal stood by its decision to retract the article due to “some clear fatal flaws” identified in letters to the editor, which it said it declined to publish due to their tone it deemed “not suitable for publication in a scientific journal.”

Highly cited engineer offers guaranteed publication, citations in return for coauthorship

Last year, a researcher at a U.S. university received an email offering what the subject line described as a “great opportunity to publish an article.”

The author of the email, Mahdi Shariati, an adjunct professor of civil engineering at Ton Duc Thang University, in Vietnam, said he had read one of the researcher’s papers and was impressed by its quality. “It would be an honor for me to collaborate with you and jointly present your remarkable work,” Shariati added.

In exchange, Shariati promised:

Reflecting on research misconduct: What’s next for the watcher community?

“At a time when scientists and scientific research are already being criticised by persons who identify science with technology and who deplore some of the consequences of technology, dishonesty among scientists causes unease among scientists themselves and regretful or gleeful misgivings among publicists who are critical of science.“

Daryl Chubin wrote that in 1985 — a time when institutions we now take for granted, like the U.S. Office of Research Integrity, did not yet exist. We asked him to reflect on what has happened in the intervening four decades.

The phrase “misconduct in research” today is a quaint reminder of how much science has been captured by for-profit, politicized, international interests. As a four-decades-removed social researcher of misconduct, I marvel at how an investigation industry has emerged to monitor, analyze, report and decry the mischief around us. This “watcher community” represents an industry in an era of science most of us never envisioned.

In the days before the Office of Research Integrity, many accused researchers and their academic institutions were grasping for an accountability structure that was fair to all parties — adhering to due process – and swift in its resolutions. Good luck! Today, the headlines in Retraction Watch reflect a publishing industry seemingly under siege—awash in retractions, plagiarism, AI mischief, undeclared conflicts of interest, whistleblowing, and a subset of ills that are dizzying and disconcerting to degrees never seen before.

Retraction Watch monitors an industry ever more self-conscious about misdeeds in research, from analysis to interpretation to reporting. By setting the threshold low, it focuses on misdeeds that may be rare in a particular field, but substantial when aggregated across fields. Yes, there is a risk of overgeneralizing from statistical anomalies, but readers care about violations that sully “their” field.

Psychology journal apologizes for paper with ‘biased language’ about Tibet

Editors of a psychology journal have published a lengthy apology for failing to identify “biased” language and information in a paper about racial prejudice of Tibetan children against Han Chinese.

The article, “The development of Tibetan children’s racial bias in empathy: The mediating role of ethnic identity and wrongfulness of ethnic intergroup bias,” appeared in Cultural Diversity & Ethnic Minority Psychology in April. It has yet to be cited, according to Clarivate’s Web of Science.

The authors listed affiliations with institutions in China, Australia, and Canada. The article describes experiments measuring the empathy – or lack thereof – Tibetan children expressed for characters with Tibetan or Han Chinese names who experienced either social or physical pain.

Exclusive: Providence VA hires scientist previous employer found had harassed mentees

The University of Iowa found a cardiology researcher violated multiple of its policies, including harassing his former mentees when they tried to leave his lab to establish labs of their own, according to an investigation report obtained by Retraction Watch.

The researcher, Kaikobad Irani, left the school last month with a six-figure settlement, and has a new job lined up, Retraction Watch has learned.

Irani studies the molecular mechanisms of the function and dysfunction of blood vessels. He’s listed as an inventor on four patents, including an active one regarding a compound that could lower the risk of heart attacks and strokes.

One of Irani’s active grants names the Providence VA Medical Center as the awardee organization. A spokesperson for the VA Providence Healthcare System confirmed Irani “is in the process of onboarding and is expected to begin working around November.”

First paper retracted in string of studies using the wrong medication name

A scientific sleuth and a mother who nearly lost her daughter to a hormonal condition teamed up in January to flag a series of papers that misnamed a medication for pregnant women. They have recently started to see the fruits of their labors: one retraction and three corrections.

In 2014, Tara Skopelitis, a lab manager at Cold Spring Harbor Laboratory, was given weekly progesterone injections to prevent preterm birth for her daughter, as reported by STAT. Six years later, after her daughter showed symptoms of an unknown hormonal condition which still hasn’t been formally diagnosed, Skopelitis discovered she should have received synthetic progesterone variant 17α-hydroxyprogesterone caproate, often referred to as 17-OHPC, 17P, sold as Makena. When the drug wasn’t available, her doctor had ordered the wrong replacement from a compounding pharmacy. Skopelitis suspects her daughter’s condition could be a result of the mixup.

The confusion lies within the literature, Skopelitis says: Many clinical trials and papers refer to 17P as intramuscular progesterone, as if they are interchangeable or even the same compound.

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: